Drugs / cefoperazone-sulbactam
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07118384 | May 2025 → Jan 2026 overdue | Acinetobacter infectious disease | Cairo University | Recruiting | No outcome recorded |
| — | NCT07671755 | Feb → Dec 2025 | — | Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cefoperazone-sulbactam | “To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii...” NCT07118384 ↗ |
| Action | Inhibit | “Sulbactam, a beta-lactamase inhibitor, is commercially available mainly in combination with β-lactam antibiotics” NCT07118384 ↗ |
| Route | Intravenous | “Cefoperazone/sulbactam IV are administered every 8 hours” NCT07118384 ↗ |